Abstract:8058 Background: Bone metastases are common in patients with breast or prostate cancer and cause significant pain and skeletal morbidity. The need for radiation to bone to treat pain or prevent a fracture is a significant clinical event associated with disease progression and quality-of-life decline. Therefore, radiation to bone was included in the composite endpoints describing skeletal morbidity in recent clinical trials of zoledronic acid. Herein, a statistically robust nonparametric method was used to measure the cumulative burden of radiation to bone over the entire course of follow-up to evaluate the benefit of 4-mg zoledronic acid in patients with breast or prostate cancer enrolled in 2 large, randomized, phase III trials. We have previously reported by this method that zoledronic acid significantly reduces the overall cumulative incidence of skeletal complications compared with placebo or pamidronate (Pam) in these patient populations. Methods: These trials were GCP-compliant, and patients gave written informed consent. Patients received 4 mg zoledronic acid via 15-minute infusion every 3–4 weeks for 2 years. Comparators were 90 mg Pam via 2-hour infusion (breast cancer) or placebo (prostate cancer). Survival-adjusted multiple event analysis was performed via the methods of Cook et al. (Stat Med 1997;16;911–924) and Ghosh and Lin (Biometrics 2000;56:554–562). Results: In patients with breast cancer (n = 766), 4 mg zoledronic acid was superior to 90 mg Pam and significantly reduced the cumulative mean number of administrations of radiation to bone by 35.4% at 25 months (P = .003), adding to the benefit achieved with Pam. Similarly, in patients with prostate cancer, 4 mg zoledronic acid significantly reduced the cumulative mean number of administrations of radiation to bone by 33.2% compared with placebo at 24 months (P = .034). Conclusion: This new, robust method provides a simple graphic representation of the cumulative need for radiation therapy and reveals the significant reduction in need for radiation therapy achieved with zoledronic acid in breast or prostate cancer patients. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceuticals Novartis (US)

Comparison of Clinical Effect in Treatment of Bone Tumor Between Zoledronic Acid Needle and Ibandronate Needle.

[Phase III Clinical Study of Zoledronic Acid in the Treatment of Pain Induced by Bone Metastasis from Solid Tumor or Multiple Myeloma].

Clinical Comparative Study of Zoledronic Acid Versus Pamidronate Disodium in the Treatment of Pain of Skeletal Metastases Lung Cancer

A multicenter randomized, double-blind and double dim comparative studies on zoledronic acid and pamidronate disodium: Phase II trials from 12 centers for treating bone metastasis pain

Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures

Randomized, Multicenter, Double - Blind, Double - Imitative, Comparative Trial of Zoledronic Acid Versus Pamidronate Disodium in the Treatment of Pain of Skeletal Metastases in Cancer Patients

Observation of the efficacy and safety of zoledronic and in postmenopausal osteoporosis

Study of Ibandronate and Alendronate Treatment for Postmenopausal Osteoporosis

Effect of zoledronic acid on blood lipid and bone mineral density in postmenopausal females

The effect of zoledronic and pamidronate acid in treating bone pain in bone metastases of malignant tumor and its impact on serum calcium and phosphorus

The effect of Zoledronic acid on pain and balance in women with postmenopausal osteoporosis

Comparison of Clinical Efficacy and Safety Between Denosumab and Alendronate in Postmenopausal Women with Osteoporosis: a Meta-Analysis

Effect of zoledronic acid on osteoprotegerin and tumor necrosis factor alpha mRNA expression in rats

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer

Dosing of zoledronic acid with its anti-tumor effects in breast cancer

Efficacy analysis of zoledronic acid combined with radiotherapy and combined with chemotherapy for bone metastasis of non-small cell lung cancer

Zoledronic Acid Reduces the Need for Radiation to Bone in Patients with Breast or Prostate Cancer Metastatic to Bone: A Survival-Adjusted Cumulative Incidence Analysis

Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials

Combined chemotherapy of zoledronic acid and pamidronate in the treatment of bone metastases from nonsmall cell lung cancer and the effects on pain stress and bone metabolic indices

Effect of 5 Mg Zoledronic Acid on Bone Mineral Density in Women with Postmenopausal Osteoporosis